

Preferred Mavyret for Hepatitis C Infection Treatment and Change to Quantity Limit for Hepatitis CM

Background:

On Jan. 1, 2023, HHSC designated one medication, Mavyret, as the primary preferred direct-acting antiviral (DAA) drug option for treating Hepatitis C infection to work toward significantly reducing chronic Hepatitis C in Medicaid patients.

Key Details:

Quantity Limit Change

HHSC intends this initiative to increase awareness, screening, diagnosis and treatment for Medicaid clients. HHSC will help improve access and adherence by allowing prescribers to write prescriptions for the entire course of therapy so clients will no longer need to request additional refills throughout their treatment duration. Prescribers may choose to write a prescription for the entire treatment cycle or have the client return for further testing if warranted.

By May 25, 2023, MCOs must update pharmacy quantity supply limits and maximum day supply coverage on DAA medications to allow access to the entire course of therapy. Prescribers may identify some clients needing to take the medication longer than others. MCOs may allow longer treatment duration upon prescriber request. MCOs must inform their providers and members of this change.

Reminder

All Medicaid clients are eligible for DAA treatment with the primary preferred agent regardless of the client's METAVIR fibrosis score, and prior authorization is not required. Any enrolled Medicaid provider can prescribe the preferred drug, and HHSC does not require a drug screening. The table below summarizes the national drug codes (NDCs) impacted by this change:

Drug Name	NDC	Jan 1, 2023 PDL status
Mavyret	00074260028 00074262528	Preferred
Epclusa	61958220101 61958220301 61958220401 61958220402 61958220501 61958220502	Non-Preferred
Vosevi	61958240101	Non-Preferred

HHSC published an update to the Texas Medicaid Preferred Drug List (PDL) on Jan. 1, 2023, designating the preferred and non-preferred options for DAA treatment. HHSC also included the changes in the daily PDL file delivered to managed care plans via TXMedConnect. PDL statuses were future-dated to reflect the Jan. 1 changes.

HHSC did not change the PDL status for all other non-preferred DAA drugs currently on the formulary. For any non-preferred DAA drugs, HHSC will continue to apply PDL prior authorization criteria for all Medicaid clients, both fee-for-service and managed care. Additionally, the following clinical prior authorization forms for Hepatitis C treatment agents have been retired and are no longer necessary:

- Antiviral Agents for Hepatitis C Virus – Initial Request (HHS Form 1335)
- Antiviral Agents for Hepatitis C Virus – Initial Request – Addendum (HHS Form 1342)

We ask MCOs to continue to remind their providers and members regarding the availability of Hepatitis C treatment coverage.

vdp-operations@hhsc.state.tx.us